Effects of intrathecal triamincinolone-acetonide treatment in MS patients with therapy-resistant spasticity

Spinal Cord

Volumn 53, Issue 2, 2015, Pages 109-113

  Kamin, F ^a,b   Rommer, P S ^a,c   Abu Mugheisib, M ^a,d   Koehler, W ^e   Hoffmann, F ^f   Winkelmann, A ^a   Benecke, R ^a   Zettl, U K ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b MVZ Hochstrae   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d KLINIKUM BRAUNSCHWEIG   (Germany)

^e Sachsisches Krankenhaus Hubertusburg   (Germany)

^f Krankenhaus Martha Maria Halle Doelau   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TRIAMCINOLONE ACETONIDE; GLUCOCORTICOID;

ADULT; ARTICLE; BLADDER FUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OPEN STUDY; OUTCOME ASSESSMENT; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; SPASTICITY; WALKING; CLINICAL TRIAL; DISABILITY; INTRASPINAL DRUG ADMINISTRATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MUSCLE SPASTICITY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; DISABILITY EVALUATION; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS, SPINAL; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MUSCLE SPASTICITY; QUALITY OF LIFE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; WALKING;

EID: 84922410146     PISSN: 13624393     EISSN: 14765624     Source Type: Journal    
DOI: 10.1038/sc.2014.155     Document Type: Article

References (20)

1. Weinshenker BG. The natural history of multiple sclerosis: update 1998. Semin Neurol 1998; 18: 301-307.
2. Zwibel HL. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther 2009; 26: 1043-1057.
3. Ginsberg D, Cruz F, Herschorn S, Gousse A, Keppenne V, Aliotta P et al. Onabotulinumtoxin A is effective in patients with urinary incontinence due to neurogenic detrusor activity regardless of concomitant anticholinergic use or neurologic etiology. Adv Ther 2013; 30: 819-833.
4. Leussink VI, Husseini L, Warnke C, Broussalis E, Hartung HP, Kieseier BC. Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity. Ther Adv Neurol Disord 2012; 5: 255-266.
5. Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 2003; 7: 1-111.
6. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Tetrazepam-containing-medicinal-products/human-referral-prac-000015.jsp&mid= WC0b01ac05805c516f. Accessed August 15, 2013.
7. Sheean G. Botulinum toxin treatment of adult spasticity: a benefit-risk assessment. Drug Saf 2006; 29: 31-48.
8. Svensson J, Borg S, Nilsson P. Costs and quality of life in multiple sclerosis patients with spasticity. Acta Neurol Scand 2014; 129: 13-20.
9. Boines GJ. Predictable remissions in multiple sclerosis. Del Med J 1963; 35: 200-202.
10. Mü ller T. Role of intraspinal steroid application in patients with multiple sclerosis. Expert Rev Neurother 2009; 9: 1279-1287.
11. Hoffmann V, Schimrigk S, Islamova S, Hellwig K, Lukas C, Brune N et al. Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients. J Neurol Sci 2003; 211: 81-84.
12. Hoffmann V, Kuhn W, Schimrigk S, Islamova S, Hellwig K, Lukas C et al. Repeat intrathecal triamcinolone acetonide application is beneficial in progressive MS patients. Eur J Neurol 2006; 13: 72-76.
13. Leussink VI, Jung S, Merschdorf U, Toyka KV, Gold R. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol 2001; 58: 91-97.
14. Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. Arthritis Rheum 1998; 41: 761-767.
15. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
16. Berger T. Multiple sclerosis spasticity daily management: retrospective data from Europe. Expert Rev Neurother 2013; 13 (3 Suppl 1), 3-7.
17. Tullman MJ. A review of current and emerging therapeutic strategies in multiple sclerosis. Am J Manag Care 2013; 19 (2 Suppl), S21-S27.
18. Patejdl R, Winkelmann A, Benecke R, Zettl UK. Muscle rupture caused by exacerbated spasticity in a patient with multiple sclerosis. J Neurol 2008; 255 (Suppl 6), 115-118.
19. Burks JS, Bigley GK, Hill HH. Rehabilitation challenges in multiple sclerosis. Ann Indian Acad Neurol 2009; 12: 296-306.
20. Hauser K, Walsh D. Visual analogue scales and assessment of quality of life in cancer. J Support Oncol 2008; 6: 277-282.